Literature DB >> 2145968

Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies.

R G Malia1, S Kitchen, M Greaves, F E Preston.   

Abstract

We have investigated the effects of purified IgG fractions from plasma containing the lupus anticoagulant (LAC) and/or IgG anticardiolipin antibody (ACA) on the degradation of factor Va by an activated protein C-protein S complex. Plasma samples from 10 patients were studied. LAC was detected by a Russell's Viper venom technique. ACA was determined by ELISA. IgG fractions were obtained from each plasma sample by protein A-Sepharose fractionation. This fraction was shown to exhibit ACA/LAC activity. Using purified activated protein C (APC), protein S and phosphatidylserine/phosphatidylcholine, factor Va degradation was assessed in the presence and absence of IgG fractions from LAC/ACA containing plasmas. After 2 min incubation the mean factor Va degradation by APC and protein S in the presence of IgG LAC/ACA fractions was 14% compared with 52% with normal IgG. A similar effect was seen when phospholipid was substituted by washed freeze-thawed platelets. Experiments employing varying concentrations of protein S and phospholipid revealed marked differences in respect of the inhibitory specificity of the different antiphospholipid antibodies. These results indicate that antiphospholipid antibodies have an inhibitory effect on the activated protein C/protein S complex and provide some explanation for a relationship between antiphospholipid antibodies and thrombosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2145968     DOI: 10.1111/j.1365-2141.1990.tb07843.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  29 in total

Review 1.  Diagnosis and management of inherited and acquired thrombophilias.

Authors:  F A Spencer; R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

Review 2.  Clinical trials for the antiphospholipid syndrome.

Authors:  J T Merrill
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

Review 3.  The antiphospholipid syndrome and atherosclerosis: clue to pathogenesis.

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

Review 4.  Antiphospholipid syndrome: multiple mechanisms.

Authors:  C G Mackworth-Young
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

Review 5.  Paradoxical thrombosis, part 2: anticoagulant and antiplatelet therapy.

Authors:  Giuseppe Lippi; Emmanuel J Favaloro; Massimo Franchini
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

Review 6.  What causes the antiphospholipid syndrome?

Authors:  J T Merrill
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

Review 7.  Mechanisms of antiphospholipid-induced thrombosis: effects on the protein C system.

Authors:  Denis Wahl; Aurélie Membre; Christine Perret-Guillaume; Véronique Regnault; Thomas Lecompte
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

Review 8.  Osteonecrosis secondary to antiphospholipid syndrome: a case report, review of the literature, and treatment strategy.

Authors:  Waqar Haque; Huseyin Kadikoy; Omar Pacha; Joseph Maliakkal; Vu Hoang; Abdul Abdellatif
Journal:  Rheumatol Int       Date:  2009-12-12       Impact factor: 2.631

9.  Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I.

Authors:  R A Roubey; C W Pratt; J P Buyon; J B Winfield
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

10.  Plasma concentrations of total/free and functional protein S are not decreased in systemic lupus erythematosus patients with lupus anticoagulant and/or antiphospholipid antibodies.

Authors:  J Matsuda; K Gohchi; M Gotoh; M Tsukamoto; N Saitoh
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.